Figure 5.

PPARγ ligands attenuate IL-1β-induced PGE₂ production in human lung fibroblasts. Primary human lung fibroblasts were pretreated with 20 μM rosiglitazone (Rosi), 1 μM CDDO, or 5 μM 15d-PGJ₂ (PGJ₂) and then cotreated with IL-1β for 24 hours as previously described. Supernatants were harvested, and PGE₂ was determined by EIA. PGE₂ production is significantly reduced in PPARγ ligand-treated fibroblasts compared to IL-1β alone (*P < .001). CDDO and 15d-PGJ₂ were significantly more potent than rosiglitazone (^† P < .05). Results are mean ± standard deviation for quadruplicate wells and are representative of 3 independent experiments that yielded similar results. Data were analyzed by ANOVA.